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Abstract An open-label, prospective, multicenter study
was conducted between October 2006 and March 2010 to
assess the efﬁcacy and safety of intravenous voriconazole
(VRCZ) as empirical therapy for antibiotic-refractory febrile
neutropenia in Japanese patients with hematological disor-
ders. In addition, to ﬁnd the patient groups that may beneﬁt
from antifungal therapy, the deﬁnition of invasive fungal
infection proposed by EORTC/MSG (2002) was assessed in
this study. Plasma (1-3)-b-D-glucan and Aspergillus PCR in
blood were also measured to improve the diagnostic accu-
racy. A total of 103 patients (median age, 59 years),
including 25 undergoing induction chemotherapies and 19
allogeneic hematopoietic cell transplants, were evaluable.
Sixty-nine percent of the patients achieved resolution of
clinical symptoms and 31 % achieved treatment success,
deﬁned as fulﬁlling the previously described ﬁve-part com-
posite endpoint. Although VRCZ was discontinued in 9.7 %
of the patients because of adverse effects, all the patients
recovered soon after discontinuation of VRCZ. The
treatment success rate of VRCZ appeared to be higher in
patients categorized as ‘‘not classiﬁed’’ compared with
‘‘possible invasive fungal disease’’ according to the EORTC/
MSG criteria. Moreover, six ‘‘not classiﬁed’’ patients were
positive for either plasma (1-3)-b-D-glucan (n = 5) or
Aspergillus PCR in blood (n = 2). The present study dem-
onstrates that empirical VRCZ therapy is safe and effective
in Japanese patients. Additionally, (1-3)-b-D-glucan and
Aspergillus PCR tests were expected to provide additional
information on the diagnosis of invasive fungal infections.
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Introduction
It is well known that invasive fungal infections (IFIs) cause
signiﬁcant morbidity and mortality in neutropenic patients
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with hematological malignancies who have undergone
intensive chemotherapy or received hematopoietic stem
cell transplantation [1–4]. Because an early diagnosis of
IFIs remains quite difﬁcult while a delay in antifungal
therapy increases mortality, empirical antifungal therapy,
triggered by persistent fever refractory to broad-spectrum
antibacterial therapy, has been the standard of care for
many decades [5, 6].
Voriconazole (VRCZ), a ﬂuconazole-derived new tria-
zole, exerts excellent antifungal activity by preventing
fungal cell growth via inhibition of fungal cytochrome
P450-dependent 14a-lanosterol demethylation, indispens-
able for the synthesis of ergosterol in fungal cell mem-
branes [7–10]. In a major, multicenter, clinical trial that
prospectively examined the efﬁcacy and safety of VRCZ as
empirical therapy, VRCZ was shown to be less toxic
compared with liposomal amphotericin B but failed to meet
the strict statistical noninferiority criteria [11]. Importantly,
however, this study strongly suggested that VRCZ reduced
the incidence of documented breakthrough invasive
aspergillosis, candidemia, and dematiaceous fungal infec-
tions, especially in the high-risk group without antifungal
prophylaxis compared with liposomal amphotericin B [11].
Moreover, in another randomized trial comparing VRCZ
and amphotericin B as target therapy for deﬁnite or prob-
able invasive pulmonary aspergillosis, not only the efﬁcacy
but also the survival rates were signiﬁcantly in favor of
VRCZ, suggesting the strong antifungal activity of VRCZ
in neutropenic patients [10]. Therefore, it is important to
conﬁrm the utility of VRCZ as empirical therapy in an
additional prospective study, although such a trial has not
been performed until now.
However, it is widely accepted that more than half of
antibiotic-resistant fevers are not caused by fungal infection;
consequently, there is a tradeoff between the beneﬁts of
empirical therapies and the adverse effects arising
from unnecessary antifungal treatments [12, 13]. Moreover,
adequate statistical evaluations in randomized comparative
studies for empirical therapy have been hampered by the
unavoidable inclusion of patientswho do not have any fungal
infection. To more effectively target patients who may
beneﬁt from antifungal therapy, therefore, various ‘‘pre-
emptive’’ approaches have recently been proposed in which
antifungal therapy is withheld until additional clinical,
mycological, or radiologic ﬁndings suggesting the presence
of an IFI are obtained [14, 15]. However, although these
preemptive approaches have been shown to reduce the
number of antifungal therapies, recent international guide-
lines concluded that it is still premature at present to intro-
duce the preemptive approach as an alternative to the
empirical approach for safety concerns [5, 6]. Therefore, to
establish safer preemptive strategies in future, it is necessary
to identify the appropriate diagnostic tools and the timing of
their use as well as to identify the patients who would beneﬁt
from such an approach.
On the basis of these observations, we conducted a
prospective multicenter trial to conﬁrm the efﬁcacy of
VRCZ as empirical therapy in Japanese patients with
hematological diseases. In addition, we analyzed the efﬁ-
cacy of VRCZ in accordance with the deﬁnitions proposed
by EORTC/MSG [16]. Furthermore, we also examined the
usefulness of the plasma (1-3)-b-D-glucan test and Asper-
gillus polymerase chain reaction (PCR) assay in blood [17–
20] to improve the diagnostic accuracy.
Patients and methods
Study design
The study was an open-label, prospective, multicenter
clinical trial of VRCZ, conducted between October 2006
and March 2010 at 21 institutions in Japan. All the insti-
tutional review boards and ethics committees of the insti-
tutions involved approved the protocol and consent form,
and written informed consent was obtained from all
patients before enrollment.
Inclusion and exclusion criteria
Patients aged 16 years or older were included if they had
received chemotherapy for hematological disorders or
hematopoietic stem cell transplantation and had febrile
neutropenia refractory to broad-spectrum antibacterial
therapy for 3 days or more. Neutropenia was deﬁned as a
neutrophil count\500/ll, or\1,000/ll with the expecta-
tion that it would further decrease to\500/ll within a few
days. Fever was deﬁned as an axillary temperature
C37.5 C or an oral temperature C38.0 C based on a
single measurement. Patients were excluded if they had
documented IFIs at study entry, severe liver dysfunction
(aminotransferase or total bilirubin levels C5 times the
upper limit of normal), renal failure (serum creatinine
C2.5 mg/dl), or a history of allergy to VRCZ or other
azoles. For study entry, prophylactic antibacterial and
antiviral therapies, or previous antifungal administration
was permitted according to each institution’s protocol, but
therapeutic use of systemic antifungal drugs was not
permitted.
Empirical therapy with VRCZ
As a general rule, VRCZ was administered intravenously,
at least for the ﬁrst 7 days, and switching to oral VRCZ
(200 mg twice per day) was permitted thereafter. For
patients with speciﬁc conditions such as renal dysfunction,
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however, the use of oral VRCZ from the beginning was
permissible. The initial loading dose of intravenous VRCZ
was 6 mg/kg twice on the ﬁrst day, followed by 4 mg/kg
twice per day. In cases in which treatment was successful,
it was recommended to continue VRCZ for 3 days after
achievement of both defervescence and neutrophil recov-
ery, or for at least 14 days in cases of persistent neutro-
penia. A treatment period of at least 7 days was set, as this
was the minimum period required before it could be con-
cluded that treatment had failed.
Before the initiation of VRCZ treatment, serum galac-
tomannan antigen (GM), plasma (1-3)-b-D-glucan, and
Aspergillus PCR in whole blood were measured together
with two sets of blood culture including mycological cul-
ture, and a chest X-ray was performed. Chest computed
tomography (CT) was recommended but was not manda-
tory in this study. All measurements of the three microbi-
ological biomarkers were performed at SRL (Tokyo,
Japan). Serum GM was measured using a one-stage
immunoenzymatic sandwich microplate assay (Platelia
Aspergillus EIA; cutoff value 0.5, Bio-Rad Laboratories)
according to the manufacturer’s instructions and was
monitored twice a week. Plasma (1-3)-b-D-glucan was also
measured twice a week in accordance with the manufac-
turer’s protocol (cutoff value, 20 pg/ml for the Fungitec
G Test; Seikagaku Corporation, Tokyo, Japan). An
Aspergillus PCR test was also performed at the end of the
therapy. The assays were performed with the ABI PRISM
7700 Sequence Detection System (lower limit of detection,
1.0 9 102 copies/ml; Applied Biosystems Japan). In brief,
genomic DNA was extracted from whole blood samples
and examined by real-time PCR using the TaqMan probe.
The sequences of PCR primers were designed to target the
highly conserved region of multicopy genes encoding the
18S ribosomal RNA of Aspergillus species (Aspergil-
lus fumigatus, A. terreus, A. niger, A. ﬂavus, and A. nidu-
lans) [21–23]. The forward primer was 50-GCGAGT
ACTGGTCCGGCTGGA-30, and the reverse primer was
50-CTAGAAACCAACAAAATAGAACCGC-30. Although
the performance of this real-time PCR system is well
established in the clinical setting for some other pathogens
including cytomegalovirus and Epstein–Barr virus [24, 25],
standardization and validation for Aspergillus species have
not yet been completed. Therefore, the objectives of using
the assay were limited to ascertaining whether it could
provide additional information in the diagnosis of invasive
Aspergillosis.
Outcome analysis
Patients were not evaluable for efﬁcacy if they had not
continued study medication for 7 or more days for a reason
other than defervescence, or toxicity or intolerance of
VRCZ. Efﬁcacy was evaluated by two outcome measures,
clinical efﬁcacy and treatment success. Clinical efﬁcacy
was deﬁned as resolution of fever regardless of neutrophil
recovery and survival for 7 days after the discontinuation
of VRCZ therapy. The deﬁnition of treatment success was
when the patient met all ﬁve criteria of the composite
endpoint as follows: (1) survival for at least 7 days after the
completion of study drug administration, (2) defervescence
for at least 48 h during neutropenia, (3) no breakthrough
fungal infection on VRCZ, (4) successful treatment of any
baseline fungal infection, and (5) no premature withdrawal
of VRCZ because of intolerance or lack of efﬁcacy as
reported in previous studies [11, 26, 27]. The baseline fungal
infection was deﬁned as documented fungal infection
found within the ﬁrst 48 h after the start of VRCZ
administration.
At study entry, patients were classiﬁed into ‘‘proven,’’
‘‘probable,’’ or ‘‘possible’’ IFI according to the criteria
proposed by EORTC/MSG in 2002 [16]. In brief, although
‘‘proven’’ IFIs were deﬁned based on deﬁnite histopathol-
ogical or mycological evidence, ‘‘probable’’ and ‘‘possi-
ble’’ IFIs were diagnosed based on three factors: host
factors, clinical features, and mycological evidence [16].
All the patients enrolled in this study had to have ‘‘febrile
neutropenia refractory to broad-spectrum antibiotics’’ as a
host factor. Therefore, the patients who either had clinical
features or for whom mycological evidence was found
were diagnosed as ‘‘possible’’ IFI, and those that had both
the clinical feature and mycological evidence were diag-
nosed as ‘‘probable’’ IFI. Among the detailed descriptions
found in the original literature [16], pulmonary lesions or
symptoms are commonly observed clinical features,
including major criteria (halo sign, air-crescent sign, cav-
ity) and minor criteria (lower respiratory symptoms, pleural
rub, nonspeciﬁc inﬁltrate). In these cases, according to the
literature, the presence of one major or two minor criteria
was regarded as a clinical feature. On the other hand,
positive GM, but not positive (1-3)-b-D-glucan and
Aspergillus PCR tests, was regarded as mycological
evidence.
The data review committee, composed of independent
experts from the Voriconazole Study Group for Febrile
Neutropenia, reviewed the validity of inclusion of all par-
ticipants, diagnosis, efﬁcacy data, and safety data. No
changes to the study were made on the basis of this review.
Safety
Safety was assessed in all patients who received at least
one dose of VRCZ. Investigators followed up adverse
events prospectively. Laboratory tests were performed at
study entry, as appropriate during therapy, and 1 week
after completion of therapy. Severe liver toxicity was
1128 J Infect Chemother (2013) 19:1126–1134
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deﬁned as[5 times the upper limit of normal of amino
transferases if B2 times the upper limit of normal at
baseline; or[10 times the upper limit of normal of amino
transferases if [2 times the upper limit of normal at
baseline. Severe nephrotoxicity was deﬁned as[2 times
the baseline level of serum creatinine if B1.5 mg/dl at
baseline; or[3 mg/dl if[1.5 mg/dl at baseline.
Statistical analysis
Clinical efﬁcacy and treatment success rates were com-
pared between categories by Fisher’s exact test. For com-
parison of two groups of data that were not normally
distributed, the Mann–Whitney U test was used. All
P values were two tailed. All statistical analyses were
performed using PASW Statistics, version 17.0 (SPSS,
Chicago, IL, USA).
Results
Patients
A total of 117 patients were enrolled in this study. Of these,
we excluded 11 participants for whom information about
outcomes was missing. We also excluded 3 participants
because the study medication was discontinued before the
elapse of 7 days even though there were no adverse events
attributable to the study drug or other deﬁnite causes. Thus,
the analytic cohort consisted of 103 patients. The baseline
characteristics of the study participants are shown in
Table 1. The median age of the patients (66 % were male)
was 59 years (range, 18–79 years). The major underlying
diseases were acute leukemia (67.9 %) and non-Hodgkin
lymphoma (15.5 %). Before study entry, 26 patients
(25.2 %) had received induction chemotherapy, 2 patients
(1.9 %) had undergone autologous hematopoietic stem cell
transplantation, and 19 (18.4 %) had received allogeneic
hematopoietic stem cell transplantation. According to the
criteria proposed by EORTC/MSG in 2002, ‘‘proven’’ IFI,
‘‘probable’’ IFI, ‘‘possible’’ IFI, or ‘‘not classiﬁed’’ was
found in 0 (0.0 %), 1 (1.0 %), 13 (12.6 %), and 89
(86.4 %) patients, respectively. The median duration of
therapy was 11 days (range, 2–37).
Efﬁcacy
Clinical efﬁcacy was demonstrated in 68.9 % of patients
whereas the treatment success rate according to the criteria of
the ﬁve-part composite endpoint was 31.1 % (Table 2).
Neither baseline nor breakthrough fungal infections were
observed in the present study. Based on the clinical decision
made at the participating institutions, seven patients were
treatedwith oralVRCZ from the beginning. In these patients,
renal dysfunction was not severe, with a median serum cre-
atinine level of 1.08 (0.70–1.34) mg/dl, and no other speciﬁc
information on clinical background was available. The
clinical efﬁcacy and treatment success rates for these patients
were 57.1 % (4/7) and 14.3 % (1/7), respectively.
Table 1 Baseline characteristics of study participants
Characteristic Total
(n = 103)
Gender, n (%)
Male 68 (66.0)
Female 35 (34.0)
Median age (range), (years) 59 (18–79)
Underlying disease, n (%)
Acute myeloid leukemia 57 (55.3)
Acute lymphoblastic leukemia 13 (12.6)
Chronic myeloid leukemia 3 (2.9)
Myelodysplastic syndrome/acute myeloid leukemia 10 (9.7)
Non-Hodgkin lymphoma 16 (15.5)
Adult T-cell leukemia/lymphoma 3 (2.9)
Aplastic anemia 1 (1.0)
ECOG performance status
0 6 (5.8)
1 42 (40.8)
2 31 (30.1)
3 22 (21.4)
4 2 (1.9)
Treatment of hematological disease, n (%)
Chemotherapy 80 (77.7)
Induction 26 (25.2)
Consolidation 14 (13.6)
Others 40 (38.8)
Autologus hematopoietic stem cell transplantation 2 (1.9)
Allogeneic hematopoietic stem cell transplantation 19 (18.4)
Missing 2 (1.9)
Classiﬁcation according to EORTC/MSG 2002 criteria, n (%)
Not classiﬁed 89 (86.4)
Possible 13 (12.6)
Probable 1 (1.0)
Proven 0 (0.0)
Chest computed tomography examination, n (%) 49 (47.6)
Neutrophil count at study entry (/ll), median (range) 2 (0–4,936)
Duration of fever before the start of voriconazole
administration (days), median (range)a
5 (2–22)
Duration of administration of voriconazole (days),
median (range)
11 (2–37)
Route of administration
Intravenous 96 (93.2)
Oral 7 (6.8)
a Two cases were not included because information was missing
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We further analyzed the differences in efﬁcacy of VRCZ
by patient subgroups categorized according to the types of
treatment for hematological diseases, EORTC/MSG crite-
ria, neutrophil counts at study entry, and duration of fever
before the start of VRCZ administration. As shown in
Table 3, no signiﬁcant difference in efﬁcacy was observed
among the subgroups categorized by type of treatment for
underlying diseases and duration of fever before the start of
VRCZ administration. However, both clinical efﬁcacy and
treatment success rates tended to be lower in the ‘‘possi-
ble’’ subgroup compared with the ‘‘not classiﬁed’’ sub-
group according to the EORTC/MSG criteria. When the
patients were categorized according to neutrophil count at
the start of VRCZ administration, the treatment success
rate, but not clinical efﬁcacy, was signiﬁcantly higher in
the groups having lower neutrophil counts. To ascertain the
reasons for these observations, we further evaluated the
duration of neutropenia after the start of VRCZ adminis-
tration in patients where treatment was clinically effective.
Among the 62 evaluable patients (neutrophil count at the
start of VRCZ \500/ll and recovered thereafter), the
duration of neutropenia in the subgroup having an initial
neutrophil count of \100/ll was 6 days (range, 2–24)
whereas that having an initial count from C100/ll to
\500 ll was 3 days (range, 1–13) (P\ 0.001). These
results make it clear that when the duration of neutropenia
is shorter after the start of VRCZ administration, the
probability of satisfying ‘‘resolution of fever during neu-
tropenia’’ (one of the components of the composite end-
point) is lower, as also discussed elsewhere [28].
Therefore, underestimation of efﬁcacy was considered to
be at least partially responsible for the lower treatment
success rate in higher neutrophil subgroups (C100/ll).
Microbiological study
Thirteen possible IFI cases according to the EORTC/MSG
classiﬁcation were diagnosed based on positive clinical
criteria, and 1 case on a positive GM test result (Table 4).
One probable IFI case was diagnosed based on positive
results for both radiologic ﬁndings and GM test. However,
5 of 6 cases with a positive (1-3)-b-D-glucan test were
categorized as ‘‘not classiﬁed’’ because neither clinical
nor mycological criteria were satisﬁed according to the
EORTC/MSG classiﬁcation (2002). In addition, two cases
Table 2 Overall efﬁcacy
Outcome measure n/n (%)
Clinical efﬁcacy 71/103 (68.9)
Treatment success using composite endpointa 32/103 (31.1)
Survival for at least 7 days after completion of
study drug administration
98/103 (95.1)
Deferverscence during neutropenia 33/103 (32.0)
No breakthrough fungal infection 103/103 (100.0)
No premature withdrawal of voriconazole
because of intolerance or lack of efﬁcacy
86/103 (83.5)
a A baseline fungal infection was not observed in this study
Table 3 Clinical efﬁcacy and treatment success rate according to treatment of hematological diseases, EORTC/MSG 2002 criteria, neutrophil
count at study entry, or duration of fever before treatment with voriconazole
Clinical efﬁcacy, n/n (%) P Treatment success, n/n (%) P
Treatment of hematological diseasesa 0.466 0.466
Chemotherapy 54/80 (67.5) 27/80 (33.8)
Autologus hematopoietic stem cell transplantation 1/2 (50.0) 0/2 (0.0)
Allogeneic hematopoietic stem cell transplantation 15/19 (78.9) 4/19 (21.1)
Classiﬁcation according to EORTC/MSG (2002) criteria 0.021 0.462
Not classiﬁed 65/89 (73.0) 30/89 (33.7)
Possible 5/13 (38.5) 2/13 (15.4)
Probable 1/1 (100.0) 0/1 (0.0)
Neutrophil count at study entry (/ll) 0.708 0.025
\100 50/72 (69.4) 28/72 (38.9)
100–499 16/25 (64.0) 4/25 (16.0)
C500 5/6 (83.3) 0/6 (0.0)
Duration of fever before treatment with voriconazole (days)a 0.828 0.831
B5 (median value) 37/54 (68.5) 18/54 (33.3)
[5 (median value) 34/47 (72.3) 14/47 (29.8)
a Two cases were not included because of missing information
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with a positive Aspergillus PCR test were also categorized
as ‘‘not classiﬁed.’’
Details of the nine patients who were positive for GM,
(1-3)-b-D-glucan, or Aspergillus PCR are listed in Table 5.
One of two patients who had a positive GM test and one of
six patients who had a positive (1-3)-b-D-glucan test had
nodular lesions with or without halo sign on chest CT,
which was strongly suggestive of invasive mold infections.
In addition, three other patients who had a positive (1-3)-b-
D-glucan test or Aspergillus PCR test had nonspeciﬁc
pulmonary signs or symptoms that met the minor clinical
criteria of the EORTC/MSG classiﬁcation.
Safety and tolerability
A safety and tolerability analysis was performed for 113
patients (Table 6). Abnormal vision, which was usually
transient, was the most common adverse effect, and was
observed frequently during the initial infusion. Liver tox-
icity was the second most common adverse effect of
VRCZ. The incidence of drug-related adverse effects was
26.5 %. Treatment with VRCZ was discontinued in 11
patients (9.7 %) because of adverse events including skin
eruption and liver dysfunction. However, none of these was
fatal, and all patients recovered soon after discontinuation
of study drug.
Discussion
Because the empirical use of VRCZ in the original report
by Walsh et al. failed to satisfy the statistical criteria for
noninferiority to liposomal amphotericin B [11], recent
guidelines have postulated VRCZ is a safe ‘‘alternative’’ to
liposomal amphotericin B [5, 6]. However, this ‘‘not non-
inferior’’ result has been debated in a series of subsequent
Table 4 Number of cases with positive clinical criteria and/or positive on microbiological tests
Required for EORTC/MSG 2002 criteria Other indirect blood tests
N Clinical criteriaa Culture GM (1-3)-b-D-glucan Aspergillus PCR
Not classiﬁed, n (%) 89 0 (0.0) 0 (0.0) 0 (0.0) 5 (5.6) 2 (2.2)
Possible, n (%) 13 12 (92.3) 0 (0.0) 1 (7.7) 1 (7.7) 0 (0.0)
Probable, n (%) 1 1 (100.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0)
a One major or two minor clinical criteria including radiologic ﬁndings or symptoms were needed
Table 5 Details of the patients who were positive by galactomannan antigen (GM), (1-3)-b-D-glucan, or Aspergillus polymerase chain reaction
(PCR) tests
Case no. GM (1-3)-b-
D-glucan
Aspergillus
PCR
Chest computed
tomography
Clinical
symptoms
EORTC/MSG
2002 criteria
Clinical efﬁcacy/
treatment success
4 ? – - Halo sign - Probable Yes/no
5 ? - - Non-speciﬁc inﬁltration - Possible Yes/yes
76 - ? - Nodular lesion - Possible Yes/yes
30 - ? - Normal - Not classiﬁed No/no
81 - ? - Normal - Not classiﬁed Yes/yes
90 - ? - Normal - Not classiﬁed No/no
94 - ? - Normal Cough, sputum Not classiﬁed Yes/no
53 - ? ? Not done Chest pain Not classiﬁed Yes/no
57 - - ? Pleural effusion - Not classiﬁed Yes/no
Table 6 Drug-related adverse events and causes of VRCZ discon-
tinuation because of adverse events (n = 113)
Drug-related adverse
events
n (%) Cause of
discontinuation
n (%)
Total 30 (26.5) 11 (9.7)
Abnormal vision 12 (10.6) Skin eruption 4 (3.5)
Liver dysfunction 6 (5.3) Liver dysfunction 2 (1.8)
Skin eruption 4 (3.5) Abnormal vision 1 (0.9)
Nausea 3 (2.7) Interstitial pneumonia 1 (0.9)
Interstitial pneumonia 1 (0.9) Dyspnea 1 (0.9)
Dyspnea 1 (0.9) Renal dysfunction 1 (0.9)
Renal dysfunction 1 (0.9) Numbness in lower
extremities
1 (0.9)
Numbness in lower
extremities
1 (0.9)
Edema 1 (0.9)
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reports, particularly because of the open-label design and
the inherent problems rising from the use of the ﬁve-part
composite endpoint [29, 30]. Moreover, a signiﬁcantly low
rate of breakthrough fungal infections as well as lower
toxicity proﬁles in the VRCZ arm, demonstrated in the
same study, suggest that there is no signiﬁcant disadvan-
tage to the patients when VRCZ is used instead of other
established antifungals. Therefore, we are of the opinion
that reevaluation of empirical VRCZ in Japanese patients
does not raise any ethical concerns, and this position was
accepted by our ethical committees. To our knowledge, this
is the second report that prospectively evaluated the efﬁ-
cacy of VRCZ using the empirical approach.
The present study demonstrated that VRCZ for empiri-
cal therapy is effective and safe in Japanese patients with
hematological diseases. However, because the treatment
success rate of seven patients who were treated with the
oral form of VRCZ seemed to be lower than those who
received the intravenous form, oral therapy would not
appear to be appropriate except in cases of severe renal
dysfunction.
To make an objective comparison with the original report
by Walsh et al. [11], we evaluated the efﬁcacy of VRCZ in
terms of both ‘‘clinical efﬁcacy’’ (assessed based on the
resolution of fever and other clinical symptoms) and
‘‘treatment success’’ using the ﬁve-part composite endpoint.
The results showed that the treatment success rate in the
present study (31.1 %) was at least comparable to that in the
original report (26.0 %). Moreover, no documented break-
through fungal infection was observed in the present study.
This ﬁnding accorded closelywith the ﬁndings in the original
report in which a low frequency of breakthrough infections
was observed in the VRCZ arm, which provides additional
evidence of the high level of efﬁcacy of VRCZ in preventing
breakthrough IFDs using the empirical approach.
The large discrepancy between the clinical efﬁcacy and
treatment success rates in this study can be almost exclu-
sively attributable to the low rate of ‘‘resolution of fever
during neutropenia’’ that was included in the composite
endpoint. As described in the ‘‘Results’’ section, the
achievement rate of this endpoint was particularly low in
the patients with higher neutrophil counts at the start of
VRCZ. This ﬁnding was in good agreement with previous
reports suggesting that signiﬁcant problems are associated
with this endpoint [28].
In this study, we further evaluated the relationship
between clinical effects of VRCZ and the probability of
fungal infection in each patient as deﬁned by the EORTC/
MSG 2002 criteria. The results showed that both the clin-
ical efﬁcacy and the treatment success rates of VRCZ were
higher in the patients categorized as ‘‘not classiﬁed’’
compared with ‘‘possible’’ IFI. However, the latter obser-
vation was not statistically signiﬁcant, possibly because the
number of the patients was insufﬁcient (Table 3). The
observation was somewhat controversial because the
majority of ‘‘not classiﬁed’’ patients are expected to have
nonfungal fever that theoretically does not respond to
VRCZ. The reasons for these observations were not elu-
cidated in the present study. However, some hypotheses
may be proposed, including (1) the ‘‘not classiﬁed’’ group
may include more responders to the antibiotics in combi-
nation with VRCZ, (2) the EORTC/MSG criteria may fail
to identify early fungal infection, (3) poor availability of
the efﬁcacy analysis method, or (4) some other mecha-
nisms that led to the resolution of fevers in the ‘‘not
classiﬁed’’ group. To gain further insight into these possi-
bilities, improvements in both diagnostic methods and
outcome analysis are vital.
As the present study was planned in 2005, we employed
the original EORTC/MSG criteria published in 2002,
not the revised version published in 2008, which has
possibly better diagnostic performance [16, 31–33]. The
revised version made a series of important corrections,
including making a CT scan mandatory for the diagnosis of
pulmonary fungal lesions. However, the present study
design did not make a CT scan mandatory, and fewer than
half of the patients actually underwent CT. Moreover, the
EORTC/MSG 2008 criteria introduced the (1-3)-b-D-glu-
can test to increase the probability of a correct diagnosis. In
addition, although the fungal PCR assay was not adopted in
the revised version, it was suggested that this assay should
be incorporated in future after the establishment of vali-
dated or standardized methods [20, 31]. In our study, six
patients diagnosed as ‘‘not classiﬁed’’ based on the 2002
criteria were positive for either (1-3)-b-D-glucan (n = 5) or
Aspergillus PCR (n = 2) (Table 5). Although this ﬁnding
suggests that these tools may increase the sensitivity of
diagnosis, we could not conﬁrm whether these patients
actually had fungal infections.
The present study has several limitations. First, the
results may have been affected by selection bias because of
the open-label, uncontrolled design of this study. Second,
we did not monitor serum VRCZ levels that might have
signiﬁcantly affected the efﬁcacy of VRCZ [34, 35].
In conclusion, the current study demonstrated that
VRCZ is a highly potent and safe agent for empirical
antifungal therapy in Japanese patients. Additionally, the
(1-3)-b-D-glucan and Aspergillus PCR tests provided
helpful information in the diagnosis of IFIs. Further
improvement to diagnostic methods must be considered to
establish effective preemptive antifungal therapy.
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